Erbguth Frank, Lange Rüdiger
Department of Neurology, Paracelsus Medical University - Nuremberg General Hospital, Breslauer Str. 201, 90471, Nürnberg, Germany.
Neurol Res Pract. 2021 Jun 1;3(1):24. doi: 10.1186/s42466-021-00123-2.
The report of a patient with blepharospasm during the COVID-19 pandemic suggested a potential ameliorating effect of wearing a face mask.
We prospectively evaluated a possible symptom change through wearing a face mask in all consecutive patients with craniofacial hyperkinesias in our botulinum toxin outpatient treatment cohort.
Patients with craniofacial hyperkinesia were asked to rate changes of symptoms between - 2 (markedly worsened), - 1 (slightly worsened), 0 (no change), + 1 (slightly improved) and + 2 (markedly improved).
Of 101 patients (19 with blepharospasm [BSP], 54 with cervical dystonia [CD], 6 with oromandibular dystonia [OMD], and 22 with hemifacial spasm [HFS]) 81 (80%) rated no symptom change, 11 (11%) symptom improvement, and 9 (9%) symptom worsening. Improvements in 9 of the 82 dystonia patients (BSP, CD, OMD) consisted of a perceived decrease in dystonic activity. 33% of dystonia patients had previously noticed or used a sensory trick. Its presence turned out to be a significant predictor of improvement during mask wearing. Deteriorations were attributed from all patients to disturbing effects of the mask interacting with facial muscle overactivity. Improvements in HSF patients were attributed to the symptom-hiding nature of the mask and not to an effect on the spasm activity itself.
Wearing a face mask did not affect self-perceived symptoms in 80% of patients with craniofacial hyperkinesis. 11% of patients reported an improvement, which occurred as sensory trick in dystonia patients and as a concealment of a stigmatizing facial expression in patients with HSF.
